Research trends for early cancer biomarker detection in Italy: An Integrated Program in Oncology (PIO) survey

Paolo Verderio, Anita Mangia, Claudio Orlando, Maurizio Belfiglio, Antonio Marchetti, Lucio Bertario, Gennaro Chiappetta, Massimo Gion, Gian Paolo Tonini, Franca Podo, Amina Vocaturo, Rosella Silvestrini, Claudio Lombardo, Angelo Paradiso, Sara Pizzamiglio, Massimo Romani, Elena Belloni, Delia Cavallo, Paola Ulivi, Stefania TommasiAgostino Steffan, Antonio Russo, Alessio Massimo, Daniele Calistri, Paola Parrella, Massimo Broggini, Antonio Giuseppe Naccarato, Fiamma Buttitta, Gaetano Finocchiaro, Giulia Veronesi, Lorena Landuzzi, Maria Benevolo, Luciano Mariani, Federico De Marco, Aldo Venuti, Gianluigi Giannelli, Michele Quaranta, Vito Trojano

Research output: Contribution to journalArticle

Abstract

Aims and background. In 2007, an Italian Research Network proposed to the Ministry of Health a concerted action aimed at developing a specific pathway for the analytical and clinical validation of new biomarkers for early cancer diagnosis. The action, funded by the Italian Ministry of Health within the Integrated Program in Oncology (PIO) and coordinated by the National Cancer Institute of Bari, started in 2008 involving 37 national research teams. Methods. To monitor the methodological and analytical needs of the studies proposed by the research teams of PIO as well as to explore the plausibility of planning external quality assessment programs for early cancer biomarker detection, the coordinating team developed an ad hoc questionnaire that was submitted to each research team. Results. From the collected data it emerged that about 70% of the biomarkers under investigation were analyzed according to nonroutine laboratory practices. The biological material utilized for biomarker assessment consisted of solid tissue (normal or pathological) in 31% of studies, serum in 21%, urine in 15%, plasma in 15%, and whole blood in 11%. Specific training of personnel directly involved in the program was reported by 18% of the teams. In 2008, only 6% of laboratories involved in PIO participated in both external quality assessment and internal quality control schemes specifically designed for the biomarkers under consideration. Standard operating procedures for the determination of about half (52%) of the biomarkers proved to be lacking in at least one phase of the biomarker assessment process. Conclusions. On the basis of these results, we decided to give priority to the application of a four-phase process for the analytical validation of new potential biomarkers by setting up and applying standard operating procedures and developing external quality assessment and internal quality control schemes as specific steps of the workflow. Free full text available at www.tumorionline.it.

Original languageEnglish
Pages (from-to)721-725
Number of pages5
JournalTumori
Volume96
Issue number5
Publication statusPublished - Sep 2010

Fingerprint

Tumor Biomarkers
Early Detection of Cancer
Italy
Biomarkers
Research
Quality Control
Critical Pathways
Process Assessment (Health Care)
National Cancer Institute (U.S.)
Workflow
Health
Surveys and Questionnaires
Urine
Serum

Keywords

  • Cancer biomarker
  • Italy
  • Survey

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Research trends for early cancer biomarker detection in Italy : An Integrated Program in Oncology (PIO) survey. / Verderio, Paolo; Mangia, Anita; Orlando, Claudio; Belfiglio, Maurizio; Marchetti, Antonio; Bertario, Lucio; Chiappetta, Gennaro; Gion, Massimo; Tonini, Gian Paolo; Podo, Franca; Vocaturo, Amina; Silvestrini, Rosella; Lombardo, Claudio; Paradiso, Angelo; Pizzamiglio, Sara; Romani, Massimo; Belloni, Elena; Cavallo, Delia; Ulivi, Paola; Tommasi, Stefania; Steffan, Agostino; Russo, Antonio; Massimo, Alessio; Calistri, Daniele; Parrella, Paola; Broggini, Massimo; Naccarato, Antonio Giuseppe; Buttitta, Fiamma; Finocchiaro, Gaetano; Veronesi, Giulia; Landuzzi, Lorena; Benevolo, Maria; Mariani, Luciano; De Marco, Federico; Venuti, Aldo; Giannelli, Gianluigi; Quaranta, Michele; Trojano, Vito.

In: Tumori, Vol. 96, No. 5, 09.2010, p. 721-725.

Research output: Contribution to journalArticle

Verderio, P, Mangia, A, Orlando, C, Belfiglio, M, Marchetti, A, Bertario, L, Chiappetta, G, Gion, M, Tonini, GP, Podo, F, Vocaturo, A, Silvestrini, R, Lombardo, C, Paradiso, A, Pizzamiglio, S, Romani, M, Belloni, E, Cavallo, D, Ulivi, P, Tommasi, S, Steffan, A, Russo, A, Massimo, A, Calistri, D, Parrella, P, Broggini, M, Naccarato, AG, Buttitta, F, Finocchiaro, G, Veronesi, G, Landuzzi, L, Benevolo, M, Mariani, L, De Marco, F, Venuti, A, Giannelli, G, Quaranta, M & Trojano, V 2010, 'Research trends for early cancer biomarker detection in Italy: An Integrated Program in Oncology (PIO) survey', Tumori, vol. 96, no. 5, pp. 721-725.
Verderio, Paolo ; Mangia, Anita ; Orlando, Claudio ; Belfiglio, Maurizio ; Marchetti, Antonio ; Bertario, Lucio ; Chiappetta, Gennaro ; Gion, Massimo ; Tonini, Gian Paolo ; Podo, Franca ; Vocaturo, Amina ; Silvestrini, Rosella ; Lombardo, Claudio ; Paradiso, Angelo ; Pizzamiglio, Sara ; Romani, Massimo ; Belloni, Elena ; Cavallo, Delia ; Ulivi, Paola ; Tommasi, Stefania ; Steffan, Agostino ; Russo, Antonio ; Massimo, Alessio ; Calistri, Daniele ; Parrella, Paola ; Broggini, Massimo ; Naccarato, Antonio Giuseppe ; Buttitta, Fiamma ; Finocchiaro, Gaetano ; Veronesi, Giulia ; Landuzzi, Lorena ; Benevolo, Maria ; Mariani, Luciano ; De Marco, Federico ; Venuti, Aldo ; Giannelli, Gianluigi ; Quaranta, Michele ; Trojano, Vito. / Research trends for early cancer biomarker detection in Italy : An Integrated Program in Oncology (PIO) survey. In: Tumori. 2010 ; Vol. 96, No. 5. pp. 721-725.
@article{943c01a400134e709613f934e1dc538a,
title = "Research trends for early cancer biomarker detection in Italy: An Integrated Program in Oncology (PIO) survey",
abstract = "Aims and background. In 2007, an Italian Research Network proposed to the Ministry of Health a concerted action aimed at developing a specific pathway for the analytical and clinical validation of new biomarkers for early cancer diagnosis. The action, funded by the Italian Ministry of Health within the Integrated Program in Oncology (PIO) and coordinated by the National Cancer Institute of Bari, started in 2008 involving 37 national research teams. Methods. To monitor the methodological and analytical needs of the studies proposed by the research teams of PIO as well as to explore the plausibility of planning external quality assessment programs for early cancer biomarker detection, the coordinating team developed an ad hoc questionnaire that was submitted to each research team. Results. From the collected data it emerged that about 70{\%} of the biomarkers under investigation were analyzed according to nonroutine laboratory practices. The biological material utilized for biomarker assessment consisted of solid tissue (normal or pathological) in 31{\%} of studies, serum in 21{\%}, urine in 15{\%}, plasma in 15{\%}, and whole blood in 11{\%}. Specific training of personnel directly involved in the program was reported by 18{\%} of the teams. In 2008, only 6{\%} of laboratories involved in PIO participated in both external quality assessment and internal quality control schemes specifically designed for the biomarkers under consideration. Standard operating procedures for the determination of about half (52{\%}) of the biomarkers proved to be lacking in at least one phase of the biomarker assessment process. Conclusions. On the basis of these results, we decided to give priority to the application of a four-phase process for the analytical validation of new potential biomarkers by setting up and applying standard operating procedures and developing external quality assessment and internal quality control schemes as specific steps of the workflow. Free full text available at www.tumorionline.it.",
keywords = "Cancer biomarker, Italy, Survey",
author = "Paolo Verderio and Anita Mangia and Claudio Orlando and Maurizio Belfiglio and Antonio Marchetti and Lucio Bertario and Gennaro Chiappetta and Massimo Gion and Tonini, {Gian Paolo} and Franca Podo and Amina Vocaturo and Rosella Silvestrini and Claudio Lombardo and Angelo Paradiso and Sara Pizzamiglio and Massimo Romani and Elena Belloni and Delia Cavallo and Paola Ulivi and Stefania Tommasi and Agostino Steffan and Antonio Russo and Alessio Massimo and Daniele Calistri and Paola Parrella and Massimo Broggini and Naccarato, {Antonio Giuseppe} and Fiamma Buttitta and Gaetano Finocchiaro and Giulia Veronesi and Lorena Landuzzi and Maria Benevolo and Luciano Mariani and {De Marco}, Federico and Aldo Venuti and Gianluigi Giannelli and Michele Quaranta and Vito Trojano",
year = "2010",
month = "9",
language = "English",
volume = "96",
pages = "721--725",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Research trends for early cancer biomarker detection in Italy

T2 - An Integrated Program in Oncology (PIO) survey

AU - Verderio, Paolo

AU - Mangia, Anita

AU - Orlando, Claudio

AU - Belfiglio, Maurizio

AU - Marchetti, Antonio

AU - Bertario, Lucio

AU - Chiappetta, Gennaro

AU - Gion, Massimo

AU - Tonini, Gian Paolo

AU - Podo, Franca

AU - Vocaturo, Amina

AU - Silvestrini, Rosella

AU - Lombardo, Claudio

AU - Paradiso, Angelo

AU - Pizzamiglio, Sara

AU - Romani, Massimo

AU - Belloni, Elena

AU - Cavallo, Delia

AU - Ulivi, Paola

AU - Tommasi, Stefania

AU - Steffan, Agostino

AU - Russo, Antonio

AU - Massimo, Alessio

AU - Calistri, Daniele

AU - Parrella, Paola

AU - Broggini, Massimo

AU - Naccarato, Antonio Giuseppe

AU - Buttitta, Fiamma

AU - Finocchiaro, Gaetano

AU - Veronesi, Giulia

AU - Landuzzi, Lorena

AU - Benevolo, Maria

AU - Mariani, Luciano

AU - De Marco, Federico

AU - Venuti, Aldo

AU - Giannelli, Gianluigi

AU - Quaranta, Michele

AU - Trojano, Vito

PY - 2010/9

Y1 - 2010/9

N2 - Aims and background. In 2007, an Italian Research Network proposed to the Ministry of Health a concerted action aimed at developing a specific pathway for the analytical and clinical validation of new biomarkers for early cancer diagnosis. The action, funded by the Italian Ministry of Health within the Integrated Program in Oncology (PIO) and coordinated by the National Cancer Institute of Bari, started in 2008 involving 37 national research teams. Methods. To monitor the methodological and analytical needs of the studies proposed by the research teams of PIO as well as to explore the plausibility of planning external quality assessment programs for early cancer biomarker detection, the coordinating team developed an ad hoc questionnaire that was submitted to each research team. Results. From the collected data it emerged that about 70% of the biomarkers under investigation were analyzed according to nonroutine laboratory practices. The biological material utilized for biomarker assessment consisted of solid tissue (normal or pathological) in 31% of studies, serum in 21%, urine in 15%, plasma in 15%, and whole blood in 11%. Specific training of personnel directly involved in the program was reported by 18% of the teams. In 2008, only 6% of laboratories involved in PIO participated in both external quality assessment and internal quality control schemes specifically designed for the biomarkers under consideration. Standard operating procedures for the determination of about half (52%) of the biomarkers proved to be lacking in at least one phase of the biomarker assessment process. Conclusions. On the basis of these results, we decided to give priority to the application of a four-phase process for the analytical validation of new potential biomarkers by setting up and applying standard operating procedures and developing external quality assessment and internal quality control schemes as specific steps of the workflow. Free full text available at www.tumorionline.it.

AB - Aims and background. In 2007, an Italian Research Network proposed to the Ministry of Health a concerted action aimed at developing a specific pathway for the analytical and clinical validation of new biomarkers for early cancer diagnosis. The action, funded by the Italian Ministry of Health within the Integrated Program in Oncology (PIO) and coordinated by the National Cancer Institute of Bari, started in 2008 involving 37 national research teams. Methods. To monitor the methodological and analytical needs of the studies proposed by the research teams of PIO as well as to explore the plausibility of planning external quality assessment programs for early cancer biomarker detection, the coordinating team developed an ad hoc questionnaire that was submitted to each research team. Results. From the collected data it emerged that about 70% of the biomarkers under investigation were analyzed according to nonroutine laboratory practices. The biological material utilized for biomarker assessment consisted of solid tissue (normal or pathological) in 31% of studies, serum in 21%, urine in 15%, plasma in 15%, and whole blood in 11%. Specific training of personnel directly involved in the program was reported by 18% of the teams. In 2008, only 6% of laboratories involved in PIO participated in both external quality assessment and internal quality control schemes specifically designed for the biomarkers under consideration. Standard operating procedures for the determination of about half (52%) of the biomarkers proved to be lacking in at least one phase of the biomarker assessment process. Conclusions. On the basis of these results, we decided to give priority to the application of a four-phase process for the analytical validation of new potential biomarkers by setting up and applying standard operating procedures and developing external quality assessment and internal quality control schemes as specific steps of the workflow. Free full text available at www.tumorionline.it.

KW - Cancer biomarker

KW - Italy

KW - Survey

UR - http://www.scopus.com/inward/record.url?scp=78650491857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650491857&partnerID=8YFLogxK

M3 - Article

C2 - 21302619

AN - SCOPUS:78650491857

VL - 96

SP - 721

EP - 725

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 5

ER -